Today: 20 May 2026
Browse Category

NYSE:MOH 23 October 2025 - 9 May 2026

UnitedHealth Stock Is Climbing Again: The Medical-Cost Bet Driving UNH Shares

UnitedHealth Stock Is Climbing Again: The Medical-Cost Bet Driving UNH Shares

UnitedHealth shares rose 2.8% to $379.98 on Friday, marking a third straight gain as investors responded to signs of easing medical-cost pressure. The company reported Q1 revenue of $111.7 billion and raised its full-year adjusted earnings outlook to over $18.25 a share. UnitedHealthcare also announced it will cut prior authorization requirements for 30% of services by the end of 2026. Humana and CVS shares also climbed sharply.
9 May 2026
···
Lumentum Holdings Stock Jumps as S&P 500 Addition Extends Nvidia-Linked AI Optics Rally (News Release Archive)

Lumentum Holdings Stock Jumps as S&P 500 Addition Extends Nvidia-Linked AI Optics Rally (News Release Archive)

Lumentum shares rose 10.6% to $617.81 in New York trading after S&P Dow Jones Indices said it will add the company to the S&P 500 on March 23. The move follows Nvidia’s $2 billion investment and a multiyear purchase agreement announced last week. Peers Coherent and Vertiv also gained. Lumentum reported second-quarter revenue up 65.5% to $665.5 million and forecast third-quarter revenue of up to $830 million.
9 March 2026
···········
UnitedHealth stock price today: UNH ticks up as Medicare Advantage rates and U.S. data loom

UnitedHealth stock price today: UNH ticks up as Medicare Advantage rates and U.S. data loom

UnitedHealth shares rose 0.3% to $277.44 in late morning trading Monday after CMS signaled a 0.09% Medicare Advantage payment increase for 2027. The stock remains under pressure after a 19% drop on Jan. 27, when the company warned of its first revenue decline since 1989. U.S. stocks were mixed, with the Dow down 0.3%. Comments on the CMS proposal are due by Feb. 25.
9 February 2026
··
Healthcare stocks in focus: Molina shock, FDA “copycat” warning and XLV set up Monday’s trade

Healthcare stocks in focus: Molina shock, FDA “copycat” warning and XLV set up Monday’s trade

Molina Healthcare plunged 25.5% after forecasting 2026 profit far below estimates and announcing a 2027 exit from Medicare Part D. Centene guided profit above expectations but dropped 3.7%, while Cigna rose 2.6% on a strong quarter but flagged a softer 2026 outlook. XLV gained 1.8%. Hims fell 10% after the FDA warned against mass-marketing compounded obesity drugs.
7 February 2026
···
UnitedHealth stock rebounds after hours as UNH recoups losses; Medicare rate debate looms

UnitedHealth stock rebounds after hours as UNH recoups losses; Medicare rate debate looms

UnitedHealth shares rose 3.4% to $277.57 Friday and gained another 3% after hours, rebounding after a volatile week for health insurers. Mizuho cut its price target on the stock to $350, citing delayed earnings recovery. Medicare Advantage rates and medical-cost trends remain key concerns. The Dow closed above 50,000, marking the strongest market gains in months.
7 February 2026
····
Dow Jones breaks 50,000 for first time as Nvidia rebounds; Wall Street turns to delayed jobs report

Dow Jones breaks 50,000 for first time as Nvidia rebounds; Wall Street turns to delayed jobs report

The Dow Jones Industrial Average closed above 50,000 for the first time Friday, ending at 50,115.67, up 2.47%. Nvidia surged 7.8% as chip stocks rallied on AI spending hopes, while Amazon dropped 5.6% after projecting $200 billion in 2026 capital expenditures. Traders await delayed U.S. jobs and inflation reports next week.
6 February 2026
····
Molina Healthcare stock dives 27% after 2026 profit outlook reset; Medicare Advantage exit looms

Molina Healthcare stock dives 27% after 2026 profit outlook reset; Medicare Advantage exit looms

Molina Healthcare shares plunged 27% to $129.77 after the company forecast 2026 adjusted EPS of at least $5.00, far below the $13.76 analyst consensus. Management cited higher medical costs and a sharp pullback in ACA Marketplace membership. The company posted a Q4 adjusted loss of $2.75 per share and plans to exit its Medicare Advantage Part D business in 2027.
6 February 2026
·
Oscar Health (OSCR) stock slips again in premarket as insurer cost fears spread ahead of earnings

Oscar Health (OSCR) stock slips again in premarket as insurer cost fears spread ahead of earnings

Oscar Health shares fell 2.3% to $12.22 in premarket trading Friday after a 5.4% drop Thursday, as investors reacted to Molina Healthcare’s profit warning and exit from Medicare Part D. Molina’s stock plunged nearly 35% after hours, dragging other managed-care stocks lower. Oscar reports earnings Feb. 10, with investors watching for updates on 2026 enrollment and claims.
6 February 2026
····
Molina Healthcare Stock (NYSE: MOH) News on Dec. 12, 2025: Rally Extends as ACA Subsidy Deadline, 2026 Outlook, and Analyst Forecasts Collide

Molina Healthcare Stock (NYSE: MOH) News on Dec. 12, 2025: Rally Extends as ACA Subsidy Deadline, 2026 Outlook, and Analyst Forecasts Collide

Molina Healthcare shares traded near $169.53 on Dec. 12, 2025, following an eighth straight session of gains. The stock’s rebound comes after a steep drop earlier in the year, with shares still well below the April high of $359.97. A new diabetes care partnership in South Carolina and renewed ACA policy uncertainty have influenced recent trading.
12 December 2025
·
MOH Stock Today, Nov. 24, 2025: Molina Healthcare Rallies on ACA Subsidy Hopes as Lawsuits and Margin Pressures Linger

MOH Stock Today, Nov. 24, 2025: Molina Healthcare Rallies on ACA Subsidy Hopes as Lawsuits and Margin Pressures Linger

Molina Healthcare shares closed up 2.6% at $145.30 Monday on heavy volume after reports of a possible extension of ACA subsidies. The stock remains down over 50% from its 52-week high following an October earnings shock and ongoing class-action lawsuits. Market cap stood at $7.5 billion, with a P/E ratio near 9x. Intraday trading ranged from $141 to $151.
24 November 2025
·

Stock Market Today

  • Celestica Inc: Over 20% Annualized Returns Anticipated Amid AI Hardware Surge
    May 19, 2026, 6:14 PM EDT. Celestica Inc (CLS) stands to gain from the growing demand for artificial intelligence (AI) hardware. This anticipated trend is expected to boost both the company's revenue (top-line) and profit margins, suggesting strong financial performance ahead. Analysts rate CLS stock as a Strong Buy, highlighting potential annualized returns exceeding 20%. Investors eyeing tech manufacturing and AI sectors may find Celestica's outlook particularly compelling amid evolving market dynamics.

Latest articles

JetBlue axes 12 routes; Fort Lauderdale responds

JetBlue axes 12 routes; Fort Lauderdale responds

20 May 2026
JetBlue will end all flights at Manchester-Boston Regional Airport on July 8 and cut nine other East Coast routes, shifting capacity to Fort Lauderdale. The move follows Spirit Airlines’ shutdown and increased competition in South Florida. JetBlue said Fort Lauderdale revenue per seat mile rose 5% in the first quarter. Manchester officials expressed disappointment, noting JetBlue made up no more than 5% of airport traffic.
Exxon, Chevron Say Oil Reserves Hit by Hormuz Choke, More Volatility Ahead

Exxon, Chevron Say Oil Reserves Hit by Hormuz Choke, More Volatility Ahead

20 May 2026
The U.S. shipped a record 9.9 million barrels from its emergency oil reserve last week, cutting stocks to 374 million barrels. Brent crude settled at $111.28 a barrel Tuesday after signs of progress in U.S.-Iran talks, but Exxon and Chevron warned the market has not fully absorbed the impact of the Strait of Hormuz closure. The IEA reported global oil inventories fell by 246 million barrels in March and April.
Toll Brothers Shares Jump on Earnings Beat, But There’s a Catch for Housing Bulls

Toll Brothers Shares Jump on Earnings Beat, But There’s a Catch for Housing Bulls

20 May 2026
Toll Brothers shares rose 2.7% to $127.50 in after-hours trading after quarterly profit and revenue topped Wall Street forecasts. Fiscal Q2 net income fell to $260.6 million from $352.4 million a year earlier, while home sales revenue dropped to $2.51 billion. The company raised its full-year delivery and pricing guidance despite high mortgage rates and softer industry sentiment.
Go toTop